Jefferies Financial Group Inc. Has $607,000 Stock Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Jefferies Financial Group Inc. decreased its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 75.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 46,800 shares of the biopharmaceutical company's stock after selling 145,974 shares during the period. Jefferies Financial Group Inc.'s holdings in Dynavax Technologies were worth $607,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of DVAX. Summit Investment Advisors Inc. boosted its position in Dynavax Technologies by 7.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company's stock worth $176,000 after buying an additional 904 shares during the period. Choreo LLC increased its position in Dynavax Technologies by 3.2% in the 1st quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after acquiring an additional 1,065 shares during the period. Russell Investments Group Ltd. raised its stake in shares of Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after acquiring an additional 1,169 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Dynavax Technologies by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock worth $401,000 after purchasing an additional 1,453 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Dynavax Technologies by 0.7% during the fourth quarter. Parkman Healthcare Partners LLC now owns 220,980 shares of the biopharmaceutical company's stock worth $2,822,000 after purchasing an additional 1,529 shares during the period. Institutional investors and hedge funds own 96.96% of the company's stock.

Dynavax Technologies Trading Down 6.6%

NASDAQ DVAX traded down $0.73 during mid-day trading on Friday, reaching $10.33. 4,776,516 shares of the stock were exchanged, compared to its average volume of 2,112,512. The stock has a market cap of $1.24 billion, a P/E ratio of -19.87 and a beta of 1.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.93 and a quick ratio of 10.84. Dynavax Technologies Corporation has a one year low of $9.22 and a one year high of $14.63. The stock has a 50 day simple moving average of $10.50 and a 200-day simple moving average of $11.56.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The firm had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. On average, analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on DVAX. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 6th. JMP Securities increased their price target on Dynavax Technologies from $31.00 to $32.00 and gave the company a "market outperform" rating in a research note on Friday. Finally, The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.